Welcome to MOLOGEN AG

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

Berlin, 15 May 2017 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) has achieved the recruitment goal with the inclusion of currently 540 patients for the pivotal IMPALA study in metastatic colorectal cancer “mCRC”. The aim of this study is to show that a switch maintenance therapy with... [more]

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presents key results of the exploratory phase II IMPULSE study. The study was designed to evaluate efficacy and safety of the Company’s lead product, the immunotherapeutic agent lefitolimod, in extensive-disease small-cell lung cancer (SCLC).... [more]

Annual Report 2016
Download PDF

 Quarterly Statement as at 31 March 2017
Download PDF